Digital AI-powered drug discovery is outpacing regulators, with Eric... During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences
Digital AI and trusted data: The key to unlocking faster, more cost-... The artificial intelligence (AI) landscape is evolving at a rapid pace.
Digital Structuring the unstructured: Deterministic AI and white box... Speed and safety in drug development and discovery represent some of the biggest challenges and opportunities facing life sciences companies today.
R&D Sponsored Patentability and predictability in AI-assisted drug discove... Artificial intelligence (AI) and machine learning (ML) are ushering in a new era in drug discovery.
Digital An investor’s perspective on bio and tech Increasingly, the life sciences world is characterised by the collision of the worlds of technology and biology.
Digital AI drug discovery: Where we are and where we’re going The promise of AI in pharma is sprouting up across the business, from marketing to manufacturing to R&D.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.